Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Zevra Therapeutics Inc. (ZVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: ZVRA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -11.7% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 425.09M USD | Price to earnings Ratio - | 1Y Target Price 21.62 |
Price to earnings Ratio - | 1Y Target Price 21.62 | ||
Volume (30-day avg) 464267 | Beta 1.98 | 52 Weeks Range 4.20 - 9.76 | Updated Date 04/1/2025 |
52 Weeks Range 4.20 - 9.76 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-26 | When After Market | Estimate -0.3986 | Actual -0.69 |
Profitability
Profit Margin - | Operating Margin (TTM) -128.01% |
Management Effectiveness
Return on Assets (TTM) -31.03% | Return on Equity (TTM) -207.84% |
Valuation
Trailing PE - | Forward PE 192.31 | Enterprise Value 395857279 | Price to Sales(TTM) 18 |
Enterprise Value 395857279 | Price to Sales(TTM) 18 | ||
Enterprise Value to Revenue 16.77 | Enterprise Value to EBITDA -4.24 | Shares Outstanding 54115900 | Shares Floating 42727184 |
Shares Outstanding 54115900 | Shares Floating 42727184 | ||
Percent Insiders 6.85 | Percent Institutions 62.98 |
Analyst Ratings
Rating 4.5 | Target Price 20.62 | Buy 4 | Strong Buy 4 |
Buy 4 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zevra Therapeutics Inc.
Company Overview
History and Background
Zevra Therapeutics, formerly KemPharm, was founded in 2006. Initially focused on prodrugs, it has evolved to acquire and develop treatments for rare diseases. The company rebranded to Zevra in 2022, reflecting its strategic shift.
Core Business Areas
- Rare Disease Therapies: Zevra focuses on acquiring, developing, and commercializing therapies for rare diseases with limited or no existing treatment options. The approach leverages market exclusivity and unmet medical needs.
- Acute Care Therapies: Develops acute care therapies to deliver quick treatment options for common ailments.
Leadership and Structure
Neil F. McFarlane serves as President and CEO. The company operates with a functional structure, emphasizing efficient development and commercialization of rare disease therapies.
Top Products and Market Share
Key Offerings
- OLPUDICu2122 (sodium phenylbutyrate): OLPUDICu2122 is used for the treatment of urea cycle disorders (UCDs). Approved by FDA in 2022. Competitors for this product include RAVICTI and BUPHENYL. Zevra is expected to be a significant share holder of the market over the next couple of years.
- AZSTARYSu00ae (serdexmethylphenidate and dexmethylphenidate): AZSTARYSu00ae is a treatment for Attention Deficit Hyperactivity Disorder (ADHD). Zevra receives royalties from Corium, a Kempharm Spin-off, on sales of AZSTARYSu00ae. Key competitors in the ADHD market include products from companies such as Teva, Noven and Tris Pharma.
Market Dynamics
Industry Overview
The rare disease therapeutics market is growing due to increased awareness, regulatory incentives, and technological advancements. This market attracts significant investment and features high barriers to entry.
Positioning
Zevra Therapeutics is positioned as a developer and commercializer of therapies for rare diseases, focusing on unmet medical needs. Their advantage lies in market exclusivity and potential for orphan drug designation.
Total Addressable Market (TAM)
The global rare disease market is estimated to be hundreds of billions. Zevra is positioned to capture a growing share within niche rare disease segments.
Upturn SWOT Analysis
Strengths
- FDA approved product (OLPUDICu2122)
- Strategic focus on rare diseases
- Royalty revenue from Azstarys
- Experienced management team
Weaknesses
- Limited product pipeline depth
- Reliance on partner royalties
- High R&D expenses
- Dependence on successful commercialization of existing products
Opportunities
- Acquisition of additional rare disease assets
- Expansion into new therapeutic areas within rare diseases
- Potential for accelerated regulatory pathways
- Leveraging orphan drug designations
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory changes
- Pricing pressure on rare disease drugs
Competitors and Market Share
Key Competitors
- HORIZON THERAPEUTICS (HZNP)
- RECORDATI (REC.MI)
- ORPHAZYME (ORPH)
Competitive Landscape
Zevra Therapeutics faces competition from larger pharmaceutical companies with established rare disease portfolios. Its advantage lies in its focused strategy and potential for orphan drug designation, as well as specific products in its portfolio. Competitors possess larger R&D budgets and more established commercial infrastructure.
Major Acquisitions
Azevan Pharmaceuticals, Inc.
- Year: 2021
- Acquisition Price (USD millions): 12.5
- Strategic Rationale: Acquisition of Azevan added KP1077 (now AZSTARYS) to KemPharm's pipeline. Now Zevara gets royalties from Corium, a spin-off of KemPharm.
Growth Trajectory and Initiatives
Historical Growth: Historically, the company's growth has been driven by strategic acquisitions and partnerships. The recent rebranding to Zevra Therapeutics marks a renewed focus on rare diseases.
Future Projections: Future growth is dependent on successful commercialization of OLPUDICu2122 and royalties from AZSTARYSu00ae, as well as future acquisitions and pipeline development.
Recent Initiatives: Recent strategic initiatives include the FDA approval and launch of OLPUDICu2122 for Urea Cycle Disorders (UCDs), and ongoing efforts to expand the rare disease portfolio.
Summary
Zevra Therapeutics is a developing biopharmaceutical company focusing on the rare disease market. Approval of OLPUDICu2122 is positive, but dependence on royalties is a vulnerability. The company faces competition from larger players and must effectively commercialize its products and continue pipeline development. Strategic acquisitions of companies in this space are key for continued growth and expansion in the space.
Similar Companies
CRBP
Corbus Pharmaceuticals Holding
CRBP
Corbus Pharmaceuticals Holding
RGNX
Regenxbio Inc
RGNX
Regenxbio Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Zevra Therapeutics Inc. Investor Relations
- Company SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary. Actual results may differ materially from projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zevra Therapeutics Inc.
Exchange NASDAQ | Headquaters Celebration, FL, United States | ||
IPO Launch date 2015-04-16 | President, CEO & Director Mr. Neil F. McFarlane | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://zevra.com |
Full time employees 59 | Website https://zevra.com | ||
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.